Abstract
Obesity is dramatically increasing virtually worldwide, which has been linked to the rising prevalence of metabolic syndrome. Excess fat accumulation causes severe alterations in adipose tissue function. Actually, adipose tissue is now recognized as a major endocrine and secretory organ that releases a wide variety of signaling molecules (hormones, growth factors, cytokines, chemokines, etc.), the adipokines, which play central roles in the regulation of energy metabolism and homeostasis, immunity and inflammation. In addition, adipose tissue is no longer regarded as a passive lipid storage site but as a highly dynamic energy depot which stores excess energy during periods of positive energy balance and mobilizes it in periods of nutrient deficiency in a tightly regulated manner. Altered lipid release and adipokine production and signaling, as occurs in obesity, are linked to insulin resistance and the associated comorbidities of metabolic syndrome (dyslipidemia, hypertension), which confer an increased risk for the development of type 2 diabetes and cardiovascular disease. Here we summarize current knowledge on adipose tissue and review the contribution of novel techniques and experimental approaches in adipobiology to the identification of novel biomarkers and potential targets for dietary or pharmacological intervention to prevent and treat adipose tissue-associated diseases.
Keywords: Adipose tissue, adipocytes, adipokines, adipoproteomics, diet, lipid metabolism, metabolic syndrome, obesity.
Current Vascular Pharmacology
Title:Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Volume: 11 Issue: 6
Author(s): Maria M. Malagon, Alberto Díaz-Ruiz, Rocio Guzman-Ruiz, Yolanda Jimenez-Gomez, Natalia R. Moreno, Socorro Garcia-Navarro, Rafael Vazquez-Martinez and Juan R. Peinado
Affiliation:
Keywords: Adipose tissue, adipocytes, adipokines, adipoproteomics, diet, lipid metabolism, metabolic syndrome, obesity.
Abstract: Obesity is dramatically increasing virtually worldwide, which has been linked to the rising prevalence of metabolic syndrome. Excess fat accumulation causes severe alterations in adipose tissue function. Actually, adipose tissue is now recognized as a major endocrine and secretory organ that releases a wide variety of signaling molecules (hormones, growth factors, cytokines, chemokines, etc.), the adipokines, which play central roles in the regulation of energy metabolism and homeostasis, immunity and inflammation. In addition, adipose tissue is no longer regarded as a passive lipid storage site but as a highly dynamic energy depot which stores excess energy during periods of positive energy balance and mobilizes it in periods of nutrient deficiency in a tightly regulated manner. Altered lipid release and adipokine production and signaling, as occurs in obesity, are linked to insulin resistance and the associated comorbidities of metabolic syndrome (dyslipidemia, hypertension), which confer an increased risk for the development of type 2 diabetes and cardiovascular disease. Here we summarize current knowledge on adipose tissue and review the contribution of novel techniques and experimental approaches in adipobiology to the identification of novel biomarkers and potential targets for dietary or pharmacological intervention to prevent and treat adipose tissue-associated diseases.
Export Options
About this article
Cite this article as:
Malagon M. Maria, Díaz-Ruiz Alberto, Guzman-Ruiz Rocio, Jimenez-Gomez Yolanda, Moreno R. Natalia, Garcia-Navarro Socorro, Vazquez-Martinez Rafael and Peinado R. Juan, Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113116660170
DOI https://dx.doi.org/10.2174/15701611113116660170 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design and Development of Solid Dispersion of Valsartan by a Lyophilization Technique: A 3<sup>2</sup> Factorial Design Approach
Micro and Nanosystems Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
Current Pharmaceutical Design Role of the Autonomic Nervous System and Neuropeptides in the Development of Obesity in Humans: Targets for Therapy?
Current Pharmaceutical Design Admission, 24 Hours and Discharge Troponin T Among Acute Myocardial Infarction Patients: Differing by Prognostic Contribution
Recent Patents on Biomarkers Gene-Gene Interactions in a Context of Individual Variability in Antipsychotic Drug Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Stem Cells Transplantation in the Treatment of Patients with Liver Failure
Current Stem Cell Research & Therapy An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Pharmacological Applications of Lignins and Lignins Related Compounds: An Overview
Current Organic Chemistry Aortic Arch Calcification and Mortality in Chronic Hemodialysis Patients
Reviews on Recent Clinical Trials The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research Psychological Problems in Female Fragile X Premutations Carriers
Current Psychiatry Reviews The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Carnosine and Kidney Diseases: What We Currently Know?
Current Medicinal Chemistry Renal COX-2, Cytokines and 20-HETE: Tubular and Vascular Mechanisms
Current Pharmaceutical Design Arterial Stiffness:A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Hypertension Reviews